Nevertheless, NB cell lines with lower SMARCA2 expression appear to be more sensitive to the loss of SMARCA4, suggesting that targeting both SMARCA2 and SMARCA4 could be a promising approach for treating NB. Here, SMARCA2 is linked to neuroblastoma.